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Supplementary Figure 1: In vitro culture of primary human germinal center B cells
(a) Immortalization of the FDC-like feeder cells (YK6) was achieved by retroviral transduction of the indicated oncogenes. Cell number was monitored by manual cell 
counting. Illustrated is time course showing the number of cells following transduction. Cohorts that had stopped proliferating and underwent replicative senescence are 
marked with an x at their final timepoint. Source data are provided as a Source Data file.
(b) Primary human B cells were cultured on membrane expressed (HK cells) versus soluble, cross-linked CD40 ligand plus IL21 or IL4.  Bar graph shows the relative 
number of viable cells after 72 hours of stimulation (n=2). Viable cells were determined by flow cytometry and counting beads. Source data are provided as a Source Data 
file.
(c) Flow cytometry analysis for the expression of CD40lg (CD154) and IL21 (transduction marker CD8a) on immortalized FDC-like cells that were engineered to express 
CD40lg and IL21. FSC, forward scatter.
(d) DLBCL primary tumor sample was transduced with retroviral vectors expressing BCL2-t2A-BCL6 and BCL2-t2A-MYC using the MuLV-GaLV fusion envelope. Cells 
were stained for transduction marker CD2 (t2A) and B cell marker CD19 and were analyzed by flow cytometry.
(e) Primary human GC B cells were transduced with the oncogenic cocktail BCL2-BCL6 and BCL2-MYC and cultured long term (Day 73). Representative flow cytometry 
analysis (n = 3) for the expression of the GC B cell markers CD38, CD20, CD19, CD80, CD22, CD95, CXCR4 and CD86. Red histograms show GC B cells compared to 
primary human naïve B cells (blue).
(f) Flow cytometry analysis for the expression of CD138 in cultured primary human GC B cells transduced with BCL2-BCL6 or BCL2-MYC was performed 4 weeks after 
transduction. FSC, forward scatter.
(g) Subtypes of cells in Figure 2e were compared using a signature of germinal center expressed genes (GCB-1). The clustering was based on the Euclidean distance 
between the average normalized expression.
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Supplementary Figure 2: CRISPR screening in transduced primary human germinal centre B cells
(a) Two different methods of Cas9 virus production were compared; Conventional transfection of 293T packaging cells with retroviral Cas9 construct was compared to a 
stable Cas9 packaging line, both tagged with BFP. Bar chart illustrates the mean fluorescence intensity of Pacific Blue (Cas9) in primary GC B cells transduced with each 
method of Cas9 virus production. Source data are provided as a Source Data file.
(b) Primary GC B cells were transduced with BCL2-BCL6 and Cas9-BFP and subsequently with gRNAs against CD19, CD22 and non-targeting control. Staining for CD19 
and CD22 was performed 6 days after gRNA transduction and gated on double positive CAS9 (BFP) and gRNA (GFP) expressing cells. Red and grey histograms show 
CD19/CD22 expression in cells transduced with the indicated gRNA and non-targeting control, respectively. 
(c) Primary GC B cells were transduced with BCL2-BCL6 and Cas9-BFP and subsequently with gRNAs against TP53, PTEN, A20, RPS6 and non-targeting control (NTC). 
Following transduction with gRNAs, enrichment or depletion of BFP+GFP+ cells was monitored by flow cytometry. Illustrated is time course showing the relative expansion 
of BFP+GFP+ cells following transduction. Source data are provided as a Source Data file.
(d) Illumina sequencing revealed the number of gRNAs present per gene in the lymphoma-focused CRISPR library. Source data are provided as a Source Data file.
(e) Flow cytometry analysis showing enrichment of double positive cells transduced by both Cas9-BFP and CRISPR library (GFP) over different timepoints in primary 
human GC B cells transduced with BCL2-BCL6.
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Supplementary Figure 3: CRISPR screening identifies GNA13 as a potent tumor suppressor gene
(a) Normalized read counts for GNA13 (9 gRNAs), CDKN2A (9 gRNAs), PTEN (8 gRNAs) compared to counts for the remaining 689 genes in the lymphoma CRISPR 
library, measured at day 70 of culture.
(b) Rank-ordered depiction of CRISPR gene scores at Day 75 (log2 scale) from highest to lowest (BCL2-MYC platform). Selected tumor suppressor genes as well as 
oncogenes are highlighted in green and red, respectively. Data points above the horizontal line are positively enriched.  
(c) HBL1-Cas9 was transduced with the lymphoma-focused CRISPR library. Genes are ranked from highest to lowest according to their CRISPR gene scores at Day 70 
(log2 scale). Selected tumor suppressor genes as well as oncogenes are highlighted in green and red, respectively. 
(d) CRISPR gene score for GNA13, TP53, CDKN2A and PTEN in GC B cells transduced with BCL2 + BCL6 (n=3, biol), HBL1 (n=1) and compared to published1 CRISPR 
gene scores in lymphoma cell lines (n=11). Error bars indicate ± s.e.m of all gRNAs targeting the indicated gene.
(e) TCGA analysis of GNA13 alteration frequency in different cancer types. Figure obtained from cBioPortal2,3 (colors were modified for clarity). 
(f) The ABC-DLBCL cell line HBL1-Cas9 was transduced with 8 gRNAs against GNA13 and 4 against non-targeting control. Cells were harvested 10 days after transduction 
and a western blot performed to validate GNA13 knock-down. β-actin was used as a loading control. Representative of > 3 experiments.
(g) HBL1-Cas9 cells were transduced with 9 GNA13, 4 PTEN and 4 non-targeting control gRNAs and enrichment or depletion of GFP+ cells was monitored by flow 
cytometry. Illustrated is time course showing the log2 fold-change relative to baseline (± s.d.) of GFP+ cells following transduction (n = 3). Representative of 3 experiments 
with 3 replicates/experiment.
(h) Cell Proliferation following GNA13 and PTEN deletion in primary human GC B cells was monitored by Vybrant™ DyeCycle™ Ruby Stain and analyzed by flow cytometry 
(n=3). GC B cells were treated with Nocodazole (1ug/ml) 24h prior to FACS analysis to arrest cells in G2 phase. Bar chart illustrates G2 positive cells of all gRNAs 
(GNA13=7, PTEN=4, NTC=4) for the indicated gene (±s.e.m). 
Source data are provided as a Source Data file for a,b,c,d,f,g and h.
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Supplementary Figure 4: Synthetic tumors formed in immunodeficient mice mimic the appearances of human DLBCL
(a) Proportion of human DLBCL biopsies expressing the indicated oncogene (BCL6, BCL2, MYC) assessed by immunohistochemistry in 
human ABC and GCB-DLBCL samples from patients enrolled in the RICOVER-60 trial; figure adapted from Staiger et al4. Source data are 
provided as a Source Data file.    (b) Immunohistochemistry images of synthetic tumors in immunodeficient mice for the indicated markers are 
shown (Magnification 20x). Six different tumors are shown. Scale bar, 100μM.
#2
9 
B
C
L6
-t2
A
-B
C
L2
 
M
Y
C
#3
5 
B
C
L6
-t2
A
-B
C
L2
 
M
Y
C
H & E
H & E
H & E H & E
H & E
H & E H & E
H & E
H & E
H & E
CD79A
CD79A
CD79A
CD79A
CD79A
CD79A
CD79A
CD79A CD79A
CD79A
CD20
CD20
CD20
CD20
CD20
CD20
CD20 CD20
CD20CD20
#2
3 
R
et
ra
ns
pl
an
t 
M
Y
C
-t2
A
-B
C
L2
 
P
53
dd
 
#2
5 
R
et
ra
ns
pl
an
t 
M
Y
C
-t2
A
-B
C
L2
 
P
53
dd
 
#3
8 
R
et
ra
ns
pl
an
t  
M
Y
C
-t2
A
-B
C
L2
 
 P
53
dd
 
C
C
N
D
3
#1
8 
B
C
L6
-t2
A
-B
C
L2
 
P
53
dd
 
#2
6 
M
Y
C
-t2
A
-B
C
L2
 
#2
4 
M
Y
C
-t2
A
-B
C
L2
 
#2
7 
M
Y
C
-t2
A
-B
C
L2
 
#3
6 
M
Y
C
-t2
A
-B
C
L2
 
Supplementary Figure 5: Synthetic tumors
Immunohistochemistry images for H&E, CD79A and CD20 are shown (Magnification 20x). Ten different tumors are shown. Scale bar, 100μM.
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Supplementary Figure 6: BCL6, BCL2 and MYC protein expression in synthetic tumors
(a) Western blot analysis showing BCL6, BCL2 and MYC protein expression in cultured untransduced, transduced (BCL2, BCL6-t2A-BCL2 or MYC-t2A-BCL2) human GC 
B cells, synthetic tumors (BCL6-t2A-BCL2+MYC and MYC-t2A-BCL2-transduced human GC B cells) and human tumors (DLBCL and Follicular lymphoma). β-actin was 
used as a loading control. Source data are provided as a Source Data file.
(b) Bar chart showing mean mRNA expression levels (TPM, ± s.d.) for BCL2 (red), BCL6 (dark blue) and MYC (light blue) in human patient samples (GOYA trial, n=504), 
lymphoma cell lines (Burkitt lymphoma n=2 (Raji, Mutu), ABC-DLBCL n=2 (TMD8, HBL1), GCB-DLBCL n=2 (SUDHL4, DOHH2)), primary GC B cells (untransduced n=3, 
BCL6-t2A-BCL2 n=3, MYC-t2A-BCL2 n=3) and synthetic tumors (BCL6-t2A-BCL2+MYC n=4, MYC-t2A-BCL2+P53dd n=3, Retransplant MYC-t2A-BCL2+P53dd n=4, 
MYC-t2A-BCL2+P53dd+CCND3 n=3, Retransplant MYC-t2A-BCL2+P53dd+CCND3 n=2).
(c) Primary human GC B cells harvested from primary tumors were retransplanted subcutaneously into NOD/SCID/gamma mice and monitored for palpable tumors. Mice 
were culled when tumors reached 12mm in size. Overall survival of the recipient mice (Primary transplant and Retransplant) is plotted as a Kaplan-Meier curve. Source 
data are provided as a Source Data file.
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Supplementary Figure 7: Phenotypic and molecular characterization of synthetic tumors 
(a) Heat map of gene expression of NF-kB signaling signatures (Supplementary Table 1) in co-cultured Germinal Centre B-cells (n=12) and synthetic tumors 
(BCL6-t2A-BCL2+MYC n=4, MYC-t2A-BCL2+P53dd n=3, Retransplant MYC-t2A-BCL2+P53dd n=4, MYC-t2A-BCL2+P53dd+CCND3 n=3, Retransplant 
MYC-t2A-BCL2+P53dd+CCND3 n=2).
(b) Gains corresponding to BCL6 on chr3 are shown. Black points are background regions whilst red and blue features correspond to genes analysed for their copy number 
state. BCL6 is indicated by arrow. 
(c) Copy number across whole genome showing no evidence of aneuploidy. Alternating colors correspond to different chromosomes. The x-axis represents bin index rather 
than absolute genomic coordinate.
(d) Flow cytometry analysis for the expression of IgM and IgG in human GC B cells transduced with BCL6-t2A-BCL2 over three different timepoints. FSC, forward scatter.
(e) Bar chart showing mRNA expression levels (TPM, ± s.d.) for immunoglobulin heavy chain constant regions, IgM (red), IgD (orange), IgG1-4 (different shades of blue), 
IgA1-2 (different shades of yellow) and IgE (grey) in lymphoma cell lines (Burkitt lymphoma n=2 (Raji, Mutu), ABC-DLBCL n=2 (TMD8, HBL1), GCB-DLBCL n=2 (SUDHL4, 
DOHH2)), primary GC B cells (untransduced n=3, BCL6-t2A-BCL2 n=3, MYC-t2A-BCL2 n=3) and synthetic tumors (BCL6-t2A-BCL2+MYC n=4, MYC-t2A-BCL2+P53dd 
n=3, Retransplant MYC-t2A-BCL2+P53dd n=4, MYC-t2A-BCL2+P53dd+CCND3 n=3, Retransplant MYC-t2A-BCL2+P53dd+CCND3 n=2). 
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Supplementary Figure 8: Gating Strategy
FACS gating strategy for 
(a) live, BFP+GFP+ (Cas9/gRNA) expressing pAKT (S473) cells as seen in Figure 4b. 
(b) live, BFP+GFP+ (Cas9/gRNA) expressing cells also positive for Annexin V as seen in Figure 4c.
(c) live, BFP+GFP+ (Cas9/gRNA) expressing cells with knockdown of CD19, CD22 or control as seen in Supplementary Figure 2b.
(d) live, BFP+GFP+ (Cas9/CRISPR library) expressing cells as seen in Supplementary Figure 2c.
(e) live, GFP+ (gRNA) expressing cells as seen in Supplementary Figure 3g.
(f) live, BFP+GFP+ (Cas9/gRNA) expressing cells with G2 cell cycle analysis as seen in Supplementary Figure 3h.
Signature name Figure Description Reference
CC-2 Figure 2 e Genes 1.33x more highly expressed in human and mouse centrocytes than centroblasts https://lymphochip.nih.gov/signaturedb/
GCB-1 Figure 2 e Fig. 3b Dave et al. NEJM 354:2431 (2006) https://lymphochip.nih.gov/signaturedb/
BCRUp-2 Figure 2 e Signaling pathway https://lymphochip.nih.gov/signaturedb/
MYCUp-2 Figure 2 e Myc_overexpression_1.5x_up https://lymphochip.nih.gov/signaturedb/
FL1 Figure 2 e Fig. 3 Dave et al. NEJM 351:2159 (2004) https://lymphochip.nih.gov/signaturedb/
STAT3Up-1 Figure 2 e Fig. 2e Lam et al. Blood. 2008 111(7):3701-13. https://lymphochip.nih.gov/signaturedb/
GCB Supplementary Figure 6 b Gene expression classifier that distinguish GCB-DLBCL and ABC-DLBCL; Genes enriched in GCB-DLBCL Dave et al. Cell 2017
ABC Supplementary Figure 6 b Gene expression classifier that distinguish GCB-DLBCL and ABC-DLBCL; Genes enriched in ABC-DLBCL Dave et al. Cell 2017
MHG Up Supplementary Figure 6 b Genes upregulated in Molecular High Grade DLBCL Sha et al. Genome Medicine 2015
MHG Down Supplementary Figure 6 b Genes downregulated in Molecular High Grade DLBCL Sha et al. Genome Medicine 2015
DHIT Up Supplementary Figure 6 b Genes upregulated in Double Hit DLBCL; Top 10 with the highest DHITsig Importance Score Ennishi et al. ﻿Journal of Clinical Oncology 2019
DHIT Down Supplementary Figure 6 b Genes downregulated in Double Hit  DLBCL; Top 10 with the lowest DHITsig Importance Score Ennishi et al. ﻿Journal of Clinical Oncology 2019
NFKB signature Supplementary Figure 7 a Union of genes from NFkB-1, NFkB-2, NFkB-3, NFkB-4, NFkB-5 signatures https://lymphochip.nih.gov/signaturedb/
Supplementary Table 1 Summary of gene signatures used in gene expression profiles. 
Oncogenic Cocktail Tumor V gene J gene CDR3 V gene mutations J gene mutations V-REGION identity nt J-REGION identity nt
MYC / BCL2 / TP53dd / CCND3 Primary IGHV3-30*03 F, IGHV3-30*18 F, IGHV3-30-5*01 F IGHJ6*02 F CAKEDYYGLGALDVW 90.09 69.57 200/222 nt 32/46 nt
MYC / BCL2 / TP53dd / CCND3 Primary IGHV3-30-3*01 F IGHJ4*02 F CARDQSRGYPFDYW 87.84 90 195/222 nt 27/30 nt
MYC / BCL2 / TP53dd / CCND3 Retransplant IGHV3-30-3*01 F IGHJ4*02 F CARDQSRGYPFDYW 87.78 93.55 194/221 nt 29/31 nt
MYC / BCL2 / TP53dd / CCND3 Retransplant IGHV3-30-3*01 F IGHJ4*02 F CARDQSRGYPFDYW 87.78 93.55 194/221 nt 29/31 nt
MYC / BCL2 / TP53dd Primary IGHV3-30*03 F, IGHV3-30*18 F, IGHV3-30*19 F, IGHV3-30-5*01 F, IGHV3-33*05 F IGHJ4*02 F CAKGYDYVWGSYRYDFDYW 84.93 93.55 186/219 nt 29/31 nt
MYC / BCL2 / TP53dd Primary IGHV3-30*03 F, IGHV3-30*18 F, IGHV3-30-5*01 F IGHJ4*02 F CAKGYDYVWGSYRYDFDYW 97.74 93.55 216/221 nt 29/31 nt
MYC / BCL2 / TP53dd Retransplant IGHV3-30*03 F, IGHV3-30*18 F, IGHV3-30*19 F, IGHV3-30-5*01 F, IGHV3-33*05 F IGHJ4*02 F CAKGYDYVWGSYRYDFDYW 84.93 93.55 186/219 nt 29/31 nt
MYC / BCL2 / TP53dd Retransplant IGHV3-30*03 F, IGHV3-30*18 F, IGHV3-30*19 F, IGHV3-30-5*01 F, IGHV3-33*05 F IGHJ4*02 F CAKGYDYVWGSYRYDFDYW 84.93 93.55 186/219 nt 29/31 nt
MYC / BCL2 / BCL6 Primary IGHV3-30*01 F, IGHV3-30-3*01 F IGHJ4*02 F CARVSSAYDLPKYYFDYW 91.4 93.55 202/221 nt 29/31 nt
MYC / BCL2 / BCL6 Primary IGHV1-2*06 F IGHJ6*03 F CARDIVVVPAAGPSYYYYMDVW 100 89.13 219/219 nt 41/46 nt
MYC / BCL2 / BCL6 Primary IGHV4-34*12 F IGHJ6*03 F CARGSLKYNYNMDVW 93.12 80.43 203/218 nt 37/46 nt
MYC / BCL2 / BCL6 Primary IGHV3-43D*04 F IGHJ4*02 F VHPIVVVPAAMGPGE#YFDYW 94.57 90.32 209/221 nt 28/31 nt
Healthy Donor 1
Healthy Donor 2
No clusters larger than 1.0% repertoire
Supplementary Table 2 Table for V and J segment mutations and identity (nt) shown for primary tumor samples (n=8) and retransplants (n=4).
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